An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma.
Zhang C, Zhang G, Sun N, Zhang Z, Xue L, Zhang Z, Yang H, Luo Y, Zheng X, Zhang Y, Yuan Y, Lei R, Yang Z, Zheng B, Wang L, Che Y, Wang F, Wang S, Gao S, Xue Q, Zhang Y, He J.
Zhang C, et al. Among authors: wang f, wang l, wang s.
Signal Transduct Target Ther. 2020 Sep 4;5(1):182. doi: 10.1038/s41392-020-00221-8.
Signal Transduct Target Ther. 2020.
PMID: 32883946
Free PMC article.